Pancreatic Islet Cell Tumors

Ulrich Knigge; Mikkel Andreassen; Birgitte Federspiel; Carsten Palnæs Hansen; Andreas Kjær; Seppo W. Langer

doi:10.1016/B978-0-12-801238-3.95812-4

Pancreatic Islet Cell Tumors

Ulrich Knigge, Mikkel Andreassen, Birgitte Federspiel, Carsten Palnæs Hansen, Andreas Kjær, Seppo W. Langer

Abstract

The incidence of pancreatic neuroendocrine neoplasms is more than 0.5/100.000. They are divided into Grade 1 (Ki67 < 2%), Grade 2 (Ki67 3%-20%), and Grade 3 (Ki67 > 20%). Tumors may be functioning (25%), that is, induce a hormone specific syndrome, or nonfunctioning (75%). Diagnosis is documented by histology, biochemistry, and somatostatin receptor imaging with CT (PET-CT). Surgery is the only treatment able to cure the patient. In patients with disseminated disease somatostatin analogs, interferon-alpha, everolimus or sunitinib is indicated in patients with a Ki67 < 20% and chemotherapy in patients with a Ki67 > 10%. Peptide receptor radionuclide therapy is an option in patients with disseminated disease and a Ki67 < 30%. Life-long follow-up is indicated in most patients.

Original language	English
Title of host publication	Encyclopedia of Endocrine Diseases
Editors	Ilpo Huhtaniemi, Luciano Martini
Publisher	Elsevier
Publication date	1 Jan 2018
Edition	2.
Pages	626-634
ISBN (Print)	9780128122006
DOIs	https://doi.org/10.1016/B978-0-12-801238-3.95812-4
Publication status	Published - 1 Jan 2018

Access to Document

10.1016/B978-0-12-801238-3.95812-4

Cite this

@inbook{8c7ba2dfb2b34cfe9231e49ea6eed6ba,

title = "Pancreatic Islet Cell Tumors",

abstract = "The incidence of pancreatic neuroendocrine neoplasms is more than 0.5/100.000. They are divided into Grade 1 (Ki67 < 2%), Grade 2 (Ki67 3%-20%), and Grade 3 (Ki67 > 20%). Tumors may be functioning (25%), that is, induce a hormone specific syndrome, or nonfunctioning (75%). Diagnosis is documented by histology, biochemistry, and somatostatin receptor imaging with CT (PET-CT). Surgery is the only treatment able to cure the patient. In patients with disseminated disease somatostatin analogs, interferon-alpha, everolimus or sunitinib is indicated in patients with a Ki67 < 20% and chemotherapy in patients with a Ki67 > 10%. Peptide receptor radionuclide therapy is an option in patients with disseminated disease and a Ki67 < 30%. Life-long follow-up is indicated in most patients.",

author = "Ulrich Knigge and Mikkel Andreassen and Birgitte Federspiel and Hansen, {Carsten Paln{\ae}s} and Andreas Kj{\ae}r and Langer, {Seppo W.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-801238-3.95812-4",

language = "English",

isbn = "9780128122006",

pages = "626--634",

editor = "Ilpo Huhtaniemi and Luciano Martini",

booktitle = "Encyclopedia of Endocrine Diseases",

publisher = "Elsevier",

address = "Netherlands",

edition = "2.",

}

TY - CHAP

T1 - Pancreatic Islet Cell Tumors

AU - Knigge, Ulrich

AU - Andreassen, Mikkel

AU - Federspiel, Birgitte

AU - Hansen, Carsten Palnæs

AU - Kjær, Andreas

AU - Langer, Seppo W.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The incidence of pancreatic neuroendocrine neoplasms is more than 0.5/100.000. They are divided into Grade 1 (Ki67 < 2%), Grade 2 (Ki67 3%-20%), and Grade 3 (Ki67 > 20%). Tumors may be functioning (25%), that is, induce a hormone specific syndrome, or nonfunctioning (75%). Diagnosis is documented by histology, biochemistry, and somatostatin receptor imaging with CT (PET-CT). Surgery is the only treatment able to cure the patient. In patients with disseminated disease somatostatin analogs, interferon-alpha, everolimus or sunitinib is indicated in patients with a Ki67 < 20% and chemotherapy in patients with a Ki67 > 10%. Peptide receptor radionuclide therapy is an option in patients with disseminated disease and a Ki67 < 30%. Life-long follow-up is indicated in most patients.

AB - The incidence of pancreatic neuroendocrine neoplasms is more than 0.5/100.000. They are divided into Grade 1 (Ki67 < 2%), Grade 2 (Ki67 3%-20%), and Grade 3 (Ki67 > 20%). Tumors may be functioning (25%), that is, induce a hormone specific syndrome, or nonfunctioning (75%). Diagnosis is documented by histology, biochemistry, and somatostatin receptor imaging with CT (PET-CT). Surgery is the only treatment able to cure the patient. In patients with disseminated disease somatostatin analogs, interferon-alpha, everolimus or sunitinib is indicated in patients with a Ki67 < 20% and chemotherapy in patients with a Ki67 > 10%. Peptide receptor radionuclide therapy is an option in patients with disseminated disease and a Ki67 < 30%. Life-long follow-up is indicated in most patients.

U2 - 10.1016/B978-0-12-801238-3.95812-4

DO - 10.1016/B978-0-12-801238-3.95812-4

M3 - Book chapter

SN - 9780128122006

SP - 626

EP - 634

BT - Encyclopedia of Endocrine Diseases

A2 - Huhtaniemi, Ilpo

A2 - Martini, Luciano

PB - Elsevier

ER -

Pancreatic Islet Cell Tumors

Abstract

Access to Document

Fingerprint

Cite this